Guardant Health (GH) Projected to Release Earnings on Thursday

Guardant Health (NASDAQ:GH) is projected to issue its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to announce earnings of ($0.41) per share and revenue of $314.23 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Guardant Health Price Performance

Shares of Guardant Health stock opened at $143.62 on Wednesday. The firm has a market cap of $19.04 billion, a price-to-earnings ratio of -42.37 and a beta of 1.59. Guardant Health has a 52-week low of $40.35 and a 52-week high of $174.08. The stock has a 50-day simple moving average of $141.31 and a 200-day simple moving average of $112.49.

Insider Buying and Selling at Guardant Health

In related news, Director Meghan V. Joyce sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $126.98, for a total value of $1,269,800.00. Following the completion of the sale, the director directly owned 11,183 shares in the company, valued at approximately $1,420,017.34. The trade was a 47.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helmy Eltoukhy sold 100,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $126.30, for a total value of $12,630,000.00. Following the sale, the chief executive officer directly owned 2,012,919 shares of the company’s stock, valued at $254,231,669.70. The trade was a 4.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 708,565 shares of company stock worth $90,556,597 in the last 90 days. Company insiders own 5.60% of the company’s stock.

Institutional Trading of Guardant Health

A number of institutional investors and hedge funds have recently modified their holdings of the company. Xponance LLC raised its stake in Guardant Health by 2.1% during the 4th quarter. Xponance LLC now owns 9,630 shares of the company’s stock worth $984,000 after buying an additional 199 shares during the period. Parallel Advisors LLC lifted its holdings in Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after acquiring an additional 219 shares in the last quarter. Wealthspire Advisors LLC lifted its holdings in Guardant Health by 6.4% during the fourth quarter. Wealthspire Advisors LLC now owns 3,886 shares of the company’s stock worth $397,000 after acquiring an additional 235 shares in the last quarter. Arax Advisory Partners grew its stake in Guardant Health by 61.5% in the fourth quarter. Arax Advisory Partners now owns 733 shares of the company’s stock valued at $75,000 after acquiring an additional 279 shares during the period. Finally, Commonwealth Equity Services LLC grew its stake in Guardant Health by 5.7% in the fourth quarter. Commonwealth Equity Services LLC now owns 6,546 shares of the company’s stock valued at $669,000 after acquiring an additional 354 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently commented on GH shares. UBS Group set a $150.00 price objective on Guardant Health in a report on Wednesday, June 24th. TD Cowen reiterated a “buy” rating on shares of Guardant Health in a research note on Thursday, July 2nd. BTIG Research boosted their target price on shares of Guardant Health from $160.00 to $190.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Wolfe Research initiated coverage on shares of Guardant Health in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 price target on the stock. Finally, Guggenheim increased their price target on shares of Guardant Health from $160.00 to $190.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $160.04.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.